Are GLP-1s the first true longevity therapies? A new era of prevention
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →About this video
Creator description · original textText language: English
This video summarises the editorial “Are GLP-1s the first longevity drugs?” published in Nature Biotechnology (2025, https://www.nature.com/articles/s41587-025-02932-1).
GLP-1 receptor agonists began as treatments for obesity and type 2 diabetes. But the last few years have revealed something far bigger: across multiple major trials, these drugs improve a wide range of age-related conditions, from cardiovascular disease and kidney decline to liver disease, sleep apnea, osteoarthritis and even all-cause mortality in high-risk groups. This unexpected breadth of benefit has triggered a serious question in the ageing field: are GLP-1s the first medicines that genuinely target multiple pathways of ageing?
AI x biology · 7 min · Source published: 2025-11-13
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.